FY2025 EPS Estimates for ADMA Biologics Decreased by Analyst

ADMA Biologics, Inc. (NASDAQ:ADMA) – Cantor Fitzgerald cut their FY2025 earnings per share (EPS) estimates for shares of ADMA Biologics in a report issued on Thursday, May 8th. Cantor Fitzgerald analyst K. Kluska now expects that the biotechnology company will post earnings of $0.72 per share for the year, down from their previous estimate of $0.73. Cantor Fitzgerald has a “Overweight” rating and a $25.00 price target on the stock. The consensus estimate for ADMA Biologics’ current full-year earnings is $0.51 per share.

ADMA has been the topic of a number of other research reports. StockNews.com lowered ADMA Biologics from a “hold” rating to a “sell” rating in a research report on Friday. Raymond James increased their target price on ADMA Biologics from $25.00 to $32.00 and gave the company a “strong-buy” rating in a report on Thursday, May 8th. One investment analyst has rated the stock with a sell rating, three have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $24.25.

ADMA Biologics Trading Up 2.4%

ADMA opened at $20.45 on Monday. ADMA Biologics has a one year low of $8.42 and a one year high of $25.67. The stock has a market capitalization of $4.86 billion, a PE ratio of 73.04 and a beta of 0.57. The business’s 50 day moving average price is $20.28 and its 200 day moving average price is $18.79. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09.

ADMA Biologics (NASDAQ:ADMA) last issued its earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.16 by ($0.02). The company had revenue of $114.80 million for the quarter, compared to analyst estimates of $116.40 million. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. The company’s revenue for the quarter was up 40.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.08 earnings per share.

Institutional Trading of ADMA Biologics

A number of hedge funds and other institutional investors have recently made changes to their positions in ADMA. GAMMA Investing LLC boosted its stake in shares of ADMA Biologics by 106.6% during the fourth quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company’s stock worth $32,000 after buying an additional 967 shares during the period. Mark Sheptoff Financial Planning LLC purchased a new position in shares of ADMA Biologics during the 4th quarter worth approximately $35,000. Skandinaviska Enskilda Banken AB publ acquired a new stake in ADMA Biologics during the first quarter worth approximately $35,000. Vision Financial Markets LLC acquired a new stake in ADMA Biologics during the fourth quarter worth approximately $51,000. Finally, Tsfg LLC acquired a new position in shares of ADMA Biologics in the 1st quarter valued at $51,000. Institutional investors and hedge funds own 75.68% of the company’s stock.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.